TMO Stock Thermo Fisher Scientific Inc.
US · NYSELast in our picks 2026-10-26 — not in the current list; analysis below is from that screen
Recovering biopharma demand, research spending, and laboratory automation provide durable growth.
Future value: $750.92 (+11.44%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Improving biopharma demand and AI-enabled laboratory opportunities.
- ▸Above 50-day MA (+4.47%)
- ▸Above 200-day MA — long-term uptrend
- ▸Near 52-week high (88.2% of range) — strength
Is TMO a buy right now?
Trend: TMO is trading above the 50-day average (+4.47%), RSI 31 — neutral momentum, with a 3-month return of +20.43%.
Valuation & quality: Thermo Fisher Scientific Inc. trades on a trailing P/E of 36.1, forward P/E 24.7, PEG 2.00, price-to-book 4.63; fundamentals show net margin 14.9%, return on equity 13.4%, revenue growth 9.1% year on year.
Analyst consensus: 25 analysts have a mean 12-month price target of $750.92 (+9.6% vs the last close; range $560.00 – $830.00), consensus rating “strong buy”.
Income: trailing dividend yield 0.28%.
Our screen: STRONG BUY (score 4) — Recovering biopharma demand, research spending, and laboratory automation provide durable growth.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -5.70% | -2.60% | +2.80% | +1.80% | +14.50% | +7.50% | +9.40% | -0.20% |
Fundamentals
Analyst price target
Technical signals
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally.
Sector: Healthcare · Industry: Diagnostics & Research · United States · 125,000 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.